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Abstract
Background: Phase 2® is a dietary supplement derived from the common white kidney bean
(Phaseolus vulgaris). Phase 2 has been shown to inhibit alpha-amylase, the complex carbohydrate
digesting enzyme, in vitro. The inhibition of alpha-amylase may result in the lowering of the effective
Glycemic Index (GI) of certain foods. The objective of this study was to determine whether the
addition of Phase 2 would lower the GI of a commercially available high glycemic food (white
bread).
Methods: An open-label 6-arm crossover study was conducted with 13 randomized subjects.
Standardized GI testing was performed on white bread with and without the addition of Phase 2 in
capsule and powder form, each in dosages of 1500 mg, 2000 mg, and 3000 mg. Statistical analysis
was performed by one-way ANOVA of all seven treatment groups using unadjusted multiple
comparisons (t tests) to the white bread control.
Results: For the capsule formulation, the 1500 mg dose had no effect on the GI and the 2000 mg
and 3000 mg capsule doses caused insignificant reductions in GI. For the powder, the 1500 mg and
2000 mg doses caused insignificant reductions in the GI, and the 3000 mg dose had a significant
effect (-20.23 or 34.11%, p = 0.023)
Conclusion: Phase 2 white bean extract appears to be a novel and potentially effective method
for reducing the GI of existing foods without modifying their ingredient profile.
Trial Registration: Trial Registration: ISRCTN50347345
Background
The glycemic index (GI) describes the blood glucose
response following consumption of a carbohydrate con-
taining test food relative to a carbohydrate containing ref-
erence food, typically glucose or white bread. The GI was
originally designed for people with diabetes as a guide to
food selection, with the advice to select foods with a low
GI. The benefits of low GI diets have been documented
with epidemiological data. Low GI diets appear to
decrease the risk of developing type II diabetes [1,2] and
coronary heart disease [3]. Controlled clinical trials show
that low GI diets can lower cholesterol [4], improve blood
sugar control (HbA1c) and insulin sensitivity in diabetics
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[5], delay the return of hunger [6], and decrease body
weight in adolescents [7,8].
The GI is defined as "the incremental area under the blood
glucose response curve of a 50 g carbohydrate portion of
a test food expressed as a percent of the response to the
same amount of carbohydrate from a standard food taken
by the same subject". The GI standardizes the glycemic
response and accounts for between subject variability by
averaging the results of testing at least 10 persons. The GI
has been shown to be reliable in mixed meal testing envi-
ronments demonstrating that the inclusion of fat or pro-
tein in a meal does not preclude the measurement of the
GI of the carbohydrate content of that meal [9-12]. Foods
have inherent GI values but there are several methods for
effectively lowering the GI of a particular food. The addi-
tion of resistant starches or fiber products (psyllium,
blackgram fiber, barley, oat beta-glucan) to the food may
lower the GI [13-19].
Alpha-amylase, secreted in the saliva and by the pancreas,
is responsible for breaking down starches into sugars that
are consequently absorbed in the small intestine. Since
the GI is a function of the rate of absorption of glucose in
the gut, inhibition of alpha-amylase may result in a low-
ering of the GI. A partially purified white bean product has
been shown to decrease post-prandial increases in plasma
glucose [20,21].
Phase 2 is a dietary supplement derived from the common
white kidney bean (Phaseolus vulgaris) that has been
shown to inhibit the digestive enzyme alpha-amylase in
vitro [22]. The objective of this study was to determine
whether Phase 2 could lower the effective GI of a common
high glycemic food product. We hypothesized that addi-
tion of the Phase 2 to white bead would affect the GI of
the white bread.
Methods
The Phase 2 product is a water extract of the white kidney
bean (Phaseolus vulgaris) standardized to alpha-amylase
(8;12;15;39) inhibiting units (Pharmachem Laboratories,
Kearny, NJ). Phase 2 is produced from non-GMO whole
white kidney beans, which are ground and then extracted
for 4 hours. The liquid is filtered and concentrated under
vacuum. The extract is filtered again, and then pasteurized
before being spray dried. The product was dosed as pow-
der (mixed in butter) and in capsule form. Phase 2 is
odorless and tasteless. Wonder brand white bread (Inter-
state Bakeries, Kansas City, MO), which was purchased at
one time, was utilized in this study.
Subjects and Study Design
Fifteen healthy volunteer subjects between the ages of 24
and 44 and a BMI between 18 and 25 (kg/m2) were
screened at the Medicus Research facility in Northridge,
CA. IRB approval was obtained from the Copernicus
Group IRB (Cary, NC) prior to any study related proce-
dures. Good Clinical Practice (GCP)'s were followed
throughout the study. All subjects gave informed consent
according to GCP guidelines prior to initiating any study
procedures. Screening fasting glucose levels were ≤ 100
mg/dL. Subjects with any active eating disorders, gastroin-
testinal illness or history of gastrointestinal surgery, diabe-
tes or other endocrinologic disorders were excluded.
Subjects underwent a history and physical examination by
a board certified physician. All women of child bearing
potential were given a urine pregnancy test and required
to use appropriate methods of contraception during the
active study. In order to standardize the glycemic response
on the each study test day, subjects were required to con-
sume only a diet of standardized prepared low-fiber fro-
zen foods [23] containing a minimum of 100 g of
carbohydrates. The purpose of the low-fiber diet is to min-
imize the potential residual blood sugar effects of slowly
digested and absorbed complex carbohydrates which may
be present up to 1 day after consuming them. Subjects
were also required to fast for 10 hours prior to their study
visit.
GI testing with 10 subjects was completed according to
the FAO/World Health Organization (WHO) guidelines
with standard methodology using glucose as the standard
food [24]. During the standardization phase of the study,
subjects reported to the study center 3 times during which
they received 50 g net carbohydrates in the form of glu-
cose. At each visit subjects had their capillary blood glu-
cose measured 9 times over 2 hours. Capillary blood
collections and multiple GI measurements were per-
formed during the two hour interval as the recommended
technique to reduce the measurement errors [25].
During the active phase of the study, subjects reported to
the study center 7 times during which they received 50 g
net carbohydrates in the form of white bread with butter
either by itself or with a form of Phase 2. The serving of
bread used to obtain 50 g of net carbohydrates was deter-
mined from the package label information. Butter was
obtained in standardized plastic "pats" and each serving
was 5 g, 36 kcal and contained 0 carbohydrates. The
amount of butter was standardized for each test dose so
that each subject received the same amount of butter at
each visit regardless of how much test product they
received. Although fat may affect the GI of foods [26],
there was consistency in the study in that it was included
in both the control and test groups. The test product was
given at dosages of 1500 mg, 2000 mg, and 3000 mg in
capsule form and 1500 mg, 2000 mg, and 3000 mg in
powder form. The powder form of the test product was
mixed into the butter which was spread on the bread. TheNutrition Journal 2009, 8:52 http://www.nutritionj.com/content/8/1/52
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capsules were taken immediately prior to the ingestion of
food. During each visit subjects again had their capillary
blood glucose measured 9 times over 2 hours.
The white bread was consumed within 5 minutes after
which subjects remained in a semi-recumbent position
throughout the duration of the study visit (unless they
need to use the restroom) to reduce variability in oro-cecal
transit time [27]. The only beverage allowed during the
testing session was ice water. The test meals were admin-
istered in a random order and the test visits were less than
2 weeks apart.
Analyses
Capillary blood was analyzed for blood glucose using the
Ascensia Contour glucometer (Bayer Healthcare,
Mishawaka, IN). Blood was drawn twice at baseline and
then at times 0 (start of meal), 15 min, 30 min, 45 min,
60 min, 90 min and 120 min.
Questionnaires
10 point Likert scales for diarrhea, flatulence, abdominal
bloating, abdominal cramping, nausea, boborygmi
(bowel sounds), and soft stools were filled out hourly and
at the end of each test period.
GI Calculation
The GI was calculated according to the FAO/WHO stand-
ard [24], which utilizes capillary blood glucose measure-
ments. As per this protocol, when a blood glucose value
fell below the baseline, only the area above the fasting
level was included.
Statistical Analysis
Statistical analysis was performed using t-tests to compare
the mean differences within groups and between the vari-
ous formulations/doses and the white bread control.
Results
Subjects
Fifteen (15) subjects were screened and 13 subjects (38%
men and 62% women) completed this 6-arm open-label
controlled crossover trial. Two subjects were withdrawn
because their blood glucose went above 200 mg/dL in the
glucose tolerance test during the standardization phase.
These individuals were excluded as they did not have a
"normal" glycemic response and may have been insulin
resistant.
Impact on GI
There was the appearance of a dose related effect of Phase
2 on the GI response to white bread with both the powder
and capsule formulations (Table 1). For the capsule for-
mulation, the 1500 mg dose had no effect on the GI and
both the 2000 mg and 3000 mg capsule doses caused
insignificant reductions in GI. For the powder, the 1500
mg and 2000 mg doses caused insignificant reductions in
the GI, and the 3000 mg dose had a significant effect (-
20.23 or 34.11%, p = 0.023)
Safety
All of the dosages and formulations appeared to be well
tolerated as there were no differences in the responses to
the 10 point Likert scale for gastric effects. No adverse
events were observed or reported during the study.
Discussion
The data from this study demonstrates decreases in the GI
of white bread with Phase 2 in both capsule and powder
formulations. The decrease was statistically significant
with the powder form at 3000 mg. The data suggest a pos-
sible dose dependent effect with a preference for the pow-
der form. The lesser effect with the capsule formulation
may reflect a reduced bioavailability of the white bean
extract, perhaps due to the time required for capsule dis-
solution.
A limitation of the study was the lack of blinding of par-
ticipants and study staff. Another limitation of the study is
its small sample size, which was based upon the FAO/
WHO guidelines for GI testing. Several methodologies
were employed to diminish the inter and intra-subject var-
iability inherent in GI testing including the use of glucose
rather than white bread during the standardization phase,
standardization of meals the day prior to each visit,
restricting the inclusion criteria to certain age and BMI cri-
Table 1: Phase 2 impact on GI
Formulation GI % Change from white bread control P Value
Control 59.3 ± 24.7
1500 mg Capsule 61.9 ± 2.6 -4.39 0.77
2000 mg Capsule 45.1 ± 14.2 24.01 0.076
3000 mg Capsule 46.8 ± 12.5 21.05 0.11
1500 mg Powder 43.6 ± 15.7 26.41 0.11
2000 mg Powder 45.2 ± 14.1 23.76 0.16
3000 mg Powder 39.1 ± 20.2 34.11 0.023
The GI of white bread control compared to the GI of white bread plus different doses and formulations of Phase 2. GI values are presented as mean 
± SD, n = 13. P values are the result of comparisons between the control and treatment values.Nutrition Journal 2009, 8:52 http://www.nutritionj.com/content/8/1/52
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terion, and the semi-recumbent position during the study
to standardize oro-cecal transit time. An inherent person-
to-person variability in these results is expected and GI
calculation as an average takes these factors into account
[28].
Previous pilot studies have been conducted with Phase 2
indicating a potential lowering of post-prandial blood
glucose levels [29]. A three arm crossover study performed
on 20 subjects compared two doses of Phase 2 (515 mg
and 750 mg in powder form mixed with food) to placebo
[30]. The subjects were given a standardized meal contain-
ing 64 g of carbohydrates (including 6 g dietary fiber and
19 g sugars). Serial glucose levels were measured every 10
minutes for 60 minutes using the One Touch Ultra blood
glucose monitoring system. The 750 mg Phase 2 group
demonstrated significantly lower blood glucose levels at
10, 20, and 30 minutes (p < 0.01) compared to both the
515 mg dose and with the placebo. The 515 mg Phase 2
group showed significantly lower blood glucose at 10, 20
(p < 0.01) and at 30 minutes (p < 0.05) compared with
placebo. The blood glucose area under the curve was
lower in the 750 mg group compared with the two other
groups, but did not reach statistical significance (p < 0.1).
These data from preliminary single meal studies suggest
that alpha-amylase inhibitors might be effective in
decreasing the absorption of glucose from a carbohydrate
containing meal, or might increase the time period over
which a single load of carbohydrates is digested. These
changes form the basis for the hypothesized mechanism
of action of alpha-amylase inhibitors in reducing the gly-
cemic index.
The benefits of reducing the effective glycemic index of
food are indicated for those with impaired glucose metab-
olism [29,31,32]. However not all clinical studies with
diabetics have been positive [33,34] and a workshop on
the subject concluded that dietary fiber may be an impor-
tant additional, independent, factor in health outcomes
[35].
The present results merit further study with a larger
number of volunteers. In addition, it would be worth-
while to determine if 2000 mg and 3000 mg doses of
powder and/or capsule forms of Phase 2 can reduce the
GI's of other high GI foods such as pasta or rice.
Conclusion
The GI of white bread was significantly decreased by the
addition of 3000 mg of the Phase 2 brand white bean
extract in powder form. Other dosages and formulations,
with the exception of the 1500 mg capsule form, showed
a trend towards a reduction in GI. With the appropriate
dose and formulation, the Phase 2 white bean extract may
be a novel and potentially effective method for reducing
the GI of existing foods without modifying their ingredi-
ent profile. Given the interest and potential benefits of
low GI diets, further studies of Phase 2 with a larger study
population and in combination with other high GI foods
are indicated.
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